Divya Gumber, MD
Advanced Heart Failure and Transplant Cardiology · Newport News, VANPI 1407250913
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 28.4% of the total. Reporting peaked in 2023 at $156 and has fallen 76.0% since, to $38 in 2025. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in VA, where the typical reported total is $4,498.
Across 14 payments — averaging $17.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$68
- Lexicon Pharmaceuticals, Inc.$51
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$38
- Abbott$32
- Kiniksa Pharmaceuticals, Ltd.$20
- Alnylam Pharmaceuticals Inc.$17
- plus $14 from 1 others
What the payments were for
- Food & beverage$239100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 4 | $68 |
| Lexicon Pharmaceuticals, Inc. | 3 | $51 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $38 |
| Abbott | 1 | $32 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Amgen | 1 | $14 |
How this compares
$239 in reported general payments places this provider in the 5th percentile of 43 advanced heart failure and transplant cardiology providers in Virginia.
See all advanced heart failure and transplant cardiology providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 27 | $30,172 |
| EntrestoSacubitril/Valsartan | 22 | $24,668 |
| JardianceEmpagliflozin | 13 | $16,764 |
| Metoprolol Succinate | 62 | $772 |
| Atorvastatin Calcium | 24 | $386 |
| Lisinopril | 32 | $317 |
| Amlodipine Besylate | 26 | $243 |
| Losartan Potassium | 12 | $106 |
| Furosemide | 11 | $69 |
Paid to pharmacies, not to this prescriber.
Other advanced heart failure and transplant cardiology in Newport News
- Amin YehyaNorfolk$398K
- John HerreChesapeake$270K
- Raymond BenzaNorfolk$141K
- Palak ShahFalls Church$112K
- Zackary TushakNorfolk$92K
- Shashank DesaiFalls Church$80K
- Keyur ShahRichmond,$62K
- Mirnela BykuCharlottesville$62K
- Edward SaweyRichmond$35K
- Michael FlanaganFalls Church$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.